Clinical trialPhase 2Recruiting
[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
A Phase 2 Study of [68Ga]BED003 for PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
- Outcome
- Ongoing
- Phase
- Phase 2
- Status
- Recruiting
- Study type
- Interventional
- Start
- 30 June 2026
- Expected end
- February 2028
- Enrollment
- 71 participants
- Sites
- 6
- Primary outcomes
- Assess the diagnostic performance of [68Ga]BED003 in the peritoneum.
- Sponsor
- Industry
- Results posted
- No
- Last update
- 15 September 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is a multi-centre, open-label, single-arm, Phase 2 study designed to evaluate the diagnostic performance of \[68Ga\]BED003 in detecting colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), invasive lobular breast cancer (ILC), and epithelial ovarian cancer (EOC).